Neuroradiological measurements for Alzheimer's dis
Post# of 154898
(Total Views: 393)
Posted On: 10/30/2024 12:51:05 AM
Neuroradiological measurements for Alzheimer's disease include:
Brain volume
Patients with Alzheimer's disease lose brain volume at a rate that's about twice the normal rate. This loss is especially pronounced in the hippocampus, where volume loss is about three times the normal rate.
Hippocampal atrophy
Hippocampal atrophy is a characteristic of Alzheimer's disease, and can be measured using MRI volumetric analysis. In older patients with mild cognitive impairment, hippocampal atrophy can predict the development of Alzheimer's disease.
Amyloid PET scans
These scans measure the amount of beta-amyloid protein in the brain, which is a hallmark of Alzheimer's disease. A positive scan indicates that Alzheimer's disease is likely the cause of a patient's symptoms.
Tau PET scans
These scans detect the accumulation of tau protein in the brain, which forms tangles in nerve cells. Tau PET scans are used to monitor the progression of Alzheimer's disease, but are not commonly used in standard medical practice.
FDG PET scans
These scans measure the brain's use of glucose, a primary source of energy for cells. FDG PET scans can provide a detailed diagnosis of brain cognitive metabolism and synaptic dysfunction.
Other neuroimaging techniques used to diagnose Alzheimer's disease include:
Structural MRI: Used to measure changes in brain morphometry, such as cortical thickness and volumetry
Diffusion-weighted imaging (DWI): Used to reveal ischemic and hypercellular lesions
Susceptibility-weighted MRI (SWI): Used to detect hemorrhage
T2-weighted MRI: Used to identify edema, encephalomalacia, and white matter changes
_____
Of course the catch is, the press release says will prove LL's efficacy --- working.
Seems like a big grab bag
1m% confident all are well versed in
Proof be in the protocol pudding.... shall see
Brain volume
Patients with Alzheimer's disease lose brain volume at a rate that's about twice the normal rate. This loss is especially pronounced in the hippocampus, where volume loss is about three times the normal rate.
Hippocampal atrophy
Hippocampal atrophy is a characteristic of Alzheimer's disease, and can be measured using MRI volumetric analysis. In older patients with mild cognitive impairment, hippocampal atrophy can predict the development of Alzheimer's disease.
Amyloid PET scans
These scans measure the amount of beta-amyloid protein in the brain, which is a hallmark of Alzheimer's disease. A positive scan indicates that Alzheimer's disease is likely the cause of a patient's symptoms.
Tau PET scans
These scans detect the accumulation of tau protein in the brain, which forms tangles in nerve cells. Tau PET scans are used to monitor the progression of Alzheimer's disease, but are not commonly used in standard medical practice.
FDG PET scans
These scans measure the brain's use of glucose, a primary source of energy for cells. FDG PET scans can provide a detailed diagnosis of brain cognitive metabolism and synaptic dysfunction.
Other neuroimaging techniques used to diagnose Alzheimer's disease include:
Structural MRI: Used to measure changes in brain morphometry, such as cortical thickness and volumetry
Diffusion-weighted imaging (DWI): Used to reveal ischemic and hypercellular lesions
Susceptibility-weighted MRI (SWI): Used to detect hemorrhage
T2-weighted MRI: Used to identify edema, encephalomalacia, and white matter changes
_____
Of course the catch is, the press release says will prove LL's efficacy --- working.
Seems like a big grab bag
1m% confident all are well versed in
Proof be in the protocol pudding.... shall see
(5)
(0)